To read the full story, subscribe or sign in.

FDA clears IND for CNTY-101 for relapsed or refractory CD19-positive B-cell malignancies

Aug. 26, 2022

The FDA has cleared Century Therapeutics' IND application to commence a phase I study of CNTY-101 in patients with relapsed or refractory CD19 positive B-cell malignancies.

BioWorld Science Immuno-oncology

Today's news in brief

BioWorld

BioWorld briefs for Jan. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for January 10, 2025

Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance

BioWorld

Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

Australia’s Celosia heads toward clinic with gene therapy for ALS

BioWorld

After raising AU$16.75 million (US$10.4 million) in a series A round, Celosia Therapeutics Pty Ltd. is heading toward the clinic with its novel gene therapy that...

Sangamo stock plunges as Pfizer leaves hemophilia partnership

BioWorld

Sangamo Therapeutics Inc.’s stock sank sharply on the last day of 2025 as Pfizer Inc. handed back the rights to their collaborative gene therapy hemophilia A...

Upgrade your daily dose of biopharma and medtech news

FDA clears IND for CNTY-101 for relapsed or refractory CD19-positive B-cell malignancies